HTC Says Its Crypto-Friendly Smartphone Will Support Litecoin

Litecoin creator Charlie Lee revealed Monday he will serve as an advisor to HTC’s Exodus, the blockchain-powered smartphone.

Fierce Biotech

NGM’s NASH drug cuts liver fat, inflammation, scarring in phase 2, shares surge

Last fall, NGM Bio unveiled data from a small group of patients showing its NASH drug cut liver fat in a phase 2 study. Now, the company is reporting results for all 78 patients in the study, showing the treatment beat placebo at reversing liver scarring and inflammation, as well as reducing liver fat buildup.

Amirah Al Idrus

Dexcom nets European approval for its G6 continuous glucose monitor in pregnant women

Dexcom has received approval in Europe extending the use of its wearable continuous glucose monitor to pregnant women across Type 1, Type 2 and gestational diabetes.

Conor Hale

Karius nets $165M from SoftBank and more to power its infection genomics test

Infectious disease blood tester Karius has raised $165 million led by SoftBank’s Vision Fund 2, the Japanese conglomerate’s upcoming sequel to its technology-focused venture capital megafund.

Conor Hale

Grifols buys antibiotic assets from bankrupt partner Aradigm

Grifols has struck a deal to buy assets from bankrupt antibiotic developer Aradigm. The agreement sees Grifols waive a $32 million debt and pay $3 million in cash to take full ownership of three assets.

Nick Paul

Repurposing Astellas' and Novartis' leukemia drugs in resistant lung cancer

University of Toronto researchers used a live-cell-based screening system to identify drugs that can enter cells and target EGFR mutations in lung cancer. In so doing, they discovered that Astellas’ Xospata and Novartis’ Rydapt, both approved to treat leukemia, may be useful in treating lung cancer patients who have developed resistance to EGFR inhibitors.

Arlene Weintraub

Biospace.com

Intersect ENT Reports Fourth Quarter and Full Year 2019 Results

Intersect ENT, Inc., a company transforming care for patients with ear, nose and throat conditions, reported financial results for the fourth quarter and full year ended December 31, 2019.

Invetx Announces $15 Million Series A Financing and Industry-leading Partnerships for Animal Biopharmaceutical Development

Invetx, a pioneering animal health biopharmaceutical company, announced a $15 million Series A financing and founding collaborations with WuXi Biologics and AbCellera.

PolyPid Announces Intention to Submit Confidential Draft Registration Statement for Proposed U.S. Initial Public Offering

PolyPid Ltd. announced that it intends to confidentially submit a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission relating to a potential initial public offering of its ordinary shares in the United States.

Zhongchao Inc. Announces Pricing of $12 Million Firm Commitment Initial Public Offering

Zhongchao Inc. announced the pricing of its initial public offering of 3,000,000 Class A ordinary shares at a public offering price of $4.00 per share.

NeuBase Therapeutics Receives Notification of Deficiency from Nasdaq Related to Delayed Quarterly Report on Form 10-QEngaged Marcum LLP as its independent registered public accounting firm

NeuBase Therapeutics, Inc. announced that it received a standard notification letter dated February 20, 2020 from The Nasdaq Stock Market LLC stating that, as a result of not having timely filed its Quarterly Report on Form 10-Q for the period ended December 31, 2019, NeuBase is not in compliance with Nasdaq Listing Rule 5250, which […]

Feedity.com/biospace

Seqirus Receives FDA Approval for FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted) for Adults 65 Years and Older

SUMMIT, N.J. , Feb. 24, 2020 /PRNewswire/ -- Quadrivalent formulation of the first-and-only adjuvanted seasonal influenza vaccine for older adults (65+ years) receives FDA approval 1 Designed with MF59® adjuvant to help strengthen, broaden and lengthen the body's immune response against the influenza strains contained in the vaccine 1,2,3,4 Seqirus announced to

Lundbeck's Vyepti Wins Approval for Preventative Treatment of Migraines

H. Lundbeck A/S is making a statement with its newly approved treatment for migraine, the first intravenous medication approved for the preventative treatment of migraine.

Esperion Wins FDA Approval for its Oral, Cholesterol-Lowering Drug

The company is planning for its drug to hit the streets by the end of March in order to provide a new option for patients with high cholesterol.

Seqirus Wins Approval for Flu Vaccine for Adults 65 and Older

Seqirus snagged approval for Fluad Quadrivalent, the first-and-only quadrivalent adjuvanted influenza vaccine developed to help protect adults 65 years and older against seasonal influenza.

FDA Action Alert: GBT’s Oxbryta and BeiGene’s Brukinsa

Here’s a look at the two drugs that had dates this week but were approved early and are now on the market.

Technology

A look at the rise of narrated articles across publications, with many partnering with apps like Audm, Curio, and Noa to produce and distribute them (Gabe Bullard/Nieman Reports)

Gabe Bullard / Nieman Reports: A look at the rise of narrated articles across publications, with many partnering with apps like Audm, Curio, and Noa to produce and distribute them — How Harvard Business Review, The New Yorker, and The Economist use audio to boost reach and retention — In spring 2016 …

Survey of 11,500+ H-1B visa holders at US tech companies finds discomfort with Trump's policies, with many feeling their place in the US is highly conditional (Sarah Emerson/OneZero )

Sarah Emerson / OneZero : Survey of 11,500+ H-1B visa holders at US tech companies finds discomfort with Trump's policies, with many feeling their place in the US is highly conditional — OneZero conducted a 10,000-person poll to shed light on the plight of H-1B workers — This article is part of Into the Valley …

As China ramps up efforts to control the narrative around the coronavirus outbreak, it is leveraging platforms like WeChat and Twitter to track down critics (David Gilbert/VICE)

David Gilbert / VICE: As China ramps up efforts to control the narrative around the coronavirus outbreak, it is leveraging platforms like WeChat and Twitter to track down critics — Joshua Left, a 28-year-old entrepreneur who runs a self-driving car startup in Wuhan, China, arrived in San Francisco in mid-January for a vacation …

Apple, TikTok decline to testify in a March congressional hearing probing their ties with China; both firms had declined to testify in a similar hearing in Nov. (Tony Romm/Washington Post)

Tony Romm / Washington Post: Apple, TikTok decline to testify in a March congressional hearing probing their ties with China; both firms had declined to testify in a similar hearing in Nov. — Apple and TikTok each have declined a request to testify at a March congressional hearing that would have probed their relationships with […]

The Open Cybersecurity Alliance introduces an open source messaging framework, OpenDXL Ontology, to create a common language between cybersecurity tools (Charlie Osborne/ZDNet)

Charlie Osborne / ZDNet: The Open Cybersecurity Alliance introduces an open source messaging framework, OpenDXL Ontology, to create a common language between cybersecurity tools — OpenDXL Ontology is designed for data and command sharing between cybersecurity software. — A new language framework designed …